Tiny Redx slammed af­ter first pa­tient is hit by ad­verse events, forc­ing a halt to can­cer drug study

The mi­cro­cap biotech Redx has lurched from a fi­nan­cial pick­le straight in­to a dam­ag­ing safe­ty is­sue with its lead drug.

The UK biotech has sus­pend­ed a Phase I/II tri­al af­ter the first pa­tient dosed ex­pe­ri­enced se­ri­ous ad­verse events that were “pos­si­bly re­lat­ed to RXC004 on-tar­get ef­fects and Wnt path­way in­hi­bi­tion. Im­por­tant­ly, analy­sis of da­ta from this first pa­tient in­di­cates that their sys­temic RXC004 ex­po­sure was sig­nif­i­cant­ly high­er than that pre­dict­ed from pre­clin­i­cal stud­ies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER